FrancophonIA/ELRC3.0 huggingface dataset:
English: In the same drug-drug interaction study assessing the effect of dexamethasone, a weaker CYP3A4 inducer, on the pharmacokinetics of bortezomib (injected intravenously), there was no significant effect on the pharmacokinetics of bortezomib based on data from 7 patients.
Danish: I det samme lægemiddelinteraktionsforsøg med undersøgelse af virkningen af dexamethason, en svagere CYP3A4-induktor, på bortezomibs farmakokinetik (som intravenøs injektion) er der ingen signifikant virkning på bortezomibs farmakokinetik, baseret på data fra 7 patienter.
English: • Changes in or abnormal bowel function
Danish: • Forandringer i afføringsmønsteret eller unormalt afføringsmønster
English: Bortezomib Hospira as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.
Danish: Bortezomib Hospira som monoterapi eller i kombination med pegyleret liposomal doxorubicin eller dexamethason er indiceret til behandling af voksne patienter med progressiv myelomatose, som tidligere har fået mindst én behandling, og som allerede har gennemgået eller er uegnede til hæmatopoietisk stamcelletransplantation.
English: • If, after Bortezomib Hospira has been held, the toxicity does not resolve, as defined above, then Bortezomib Hospira must be discontinued.
Danish: • Seponér Bortezomib Hospira, hvis toksiciteten ikke svinder efter afbrydelse af behandlingen som defineret ovenfor.
English: p-value c
Danish: p-værdi d
English: Common Herpes zoster (inc disseminated & ophthalmic), Pneumonia*, Herpes simplex*, Fungal infection*
Danish: dissemineret og oftalmisk), pneumoni*, herpes simplex*, svampeinfektion*
English: • Infections, including pneumonia, respiratory infections, bronchitis, fungal infections, coughing with phlegm, flu like illness
Danish: • Infektioner, herunder lungebetændelse, luftvejsinfektioner, bronkitis, svampeinfektioner, hoste med slim, influenzalignende sygdom
English: Refers to response rate after second transplant for subjects who received a second transplant (42/240 [18% ]
Danish: Henviser til responsrate efter den anden transplantation hos patienter, der blev transplanteret 2 gange
English: In Cycles 5-9, Bortezomib Hospira is administered once weekly on days 1, 8, 22 and 29.
Danish: I cyklus 5-9 indgives Bortezomib Hospira én gang om ugen på dag 1, 8, 22 og 29.
English: Very common side effects (may affect more than 1 in 10 people)
Danish: Meget almindelige bivirkninger (kan forekomme hos mere end 1 ud af 10 patienter)
English: Day
Danish: -- Dag
English: However, the chemical and physical in-use stability of the reconstituted solution has been demonstrated for 8 hours at 5°C and 25°C stored in the original vial and/or a syringe.
Danish: Der er dog påvist kemisk og fysisk stabilitet for det rekonstituerede produkt i 8 timer ved 5°C og 25°C, når det opbevares i det originale hætteglas og/eller i en sprøjte.
English: • Heartburn, bloating, belching, wind, stomach pain, bleeding from your bowels or stomach
Danish: • Halsbrand, oppustethed, ræben, luft i tarmene, mavesmerter, blødning fra tarme eller mave
English: Posology for patients with previously untreated mantle cell lymphoma (MCL) Combination therapy with rituximab, cyclophosphamide, doxorubicin and prednisone (BR-CAP) Bortezomib Hospira is administered via intravenous or subcutaneous injection at the recommended dose of 1.3 mg/m2 body surface area twice weekly for two weeks on days 1, 4, 8 and 11, followed by a 10-day rest period on days 12-21.
Danish: Dosering til patienter med tidligere ubehandlet mantle-celle-lymfom (MCL) Kombinationsbehandling med rituximab, cyclophosphamid, doxorubicin og prednison (BR-CAP) Bortezomib Hospira administreres via intravenøs eller subkutan injektion i den anbefalede dosis på 1,3 mg/m2 legemsoverfladeareal 2 gange om ugen i 2 uger på dag 1, 4, 8 og 11 efterfulgt af en 10-dages pause på dag 12-21.
English: In Cycles 1-4, Bortezomib Hospira is administered twice weekly on days 1, 4, 8, 11, 22, 25, 29 and 32.
Danish: I cyklus 1-4 indgives Bortezomib Hospira 2 gange om ugen på dag 1, 4, 8, 11, 22, 25, 29 og 32.
English: However, the chemical and physical in-use stability has been demonstrated for 8 hours at 5°C and 25°C stored in the original vial and/or a syringe.
Danish: Der er dog påvist kemisk og fysisk stabilitet i 8 timer ved 5°C og 25°C, når produktet opbevares i det originale hætteglas og/eller en sprøjte.
English: • Fracture
Danish: • Knoglebrud
English: Thalidomide is administered orally at 50 mg daily on days 1-14 and if tolerated the dose is increased to 100 mg on days 15-28, and thereafter may be further increased to 200 mg daily from cycle 2 (see Table 4).
Danish: Thalidomid administreres oralt i en dosis på 50 mg dagligt på dag 1-14 og forhøjes, hvis denne dosis tolereres, til 100 mg på dag 15-28.
English: Bortezomib Hospira is available for intravenous or subcutaneous administration.
Danish: Bortezomib Hospira fås til intravenøs eller subkutan administration.
English: Cerebral haemorrhage*, Haemorrhage intracranial (inc subarachnoid)*, Brain oedema, Transient ischaemic attack, Coma, Autonomic nervous system imbalance, Autonomic neuropathy, Cranial palsy*, Paralysis*, Paresis*, Presyncope, Brain stem syndrome, Cerebrovascular disorder, Nerve root lesion, Psychomotor hyperactivity, Spinal cord compression, Cognitive disorder NOS, Motor dysfunction, Nervous system disorder NOS, Radiculitis, Drooling, Hypotonia
Danish: subaraknoidal-blødning)*, hjerneødem, transitorisk cerebral iskæmi (TCI), koma, ubalance i det autonome nervesystem, autonom neuropati, kraniel parese*, paralyse*, parese*, præsynkope, hjernestammesyndrom, cerebrovaskulær sygdom, nerverodsskade, psykomotorisk hyperaktivitet, kompression af rygmarven, uspecificeret kognitiv forstyrrelse, motorisk dysfunktion, uspecificeret sygdom i nervesystemet, radikulitis, savlen, hypotoni
English: Very Common Nausea and vomiting symptoms*, Diarrhoea*, Stomatitis*, Constipation
Danish: Meget almindelig Kvalme og opkastning*, diarré*, stomatitis*, obstipation Almindelig
English: • Muscle cramps, muscle spasms, muscle weakness, pain in your limbs
Danish: • Muskelkramper, muskelspasmer, muskelsvaghed, smerter i arme og ben
English: A drug-drug interaction study assessing the effect of melphalan-prednisone on the pharmacokinetics of bortezomib (injected intravenously), showed a mean bortezomib AUC increase of 17% based on data from 21 patients.
Danish: Et lægemiddelinteraktionsforsøg med undersøgelse af virkningen af melphalan-prednison på bortezomibs farmakokinetik (som intravenøs injektion) viser en gennemsnitlig stigning i bortezomibs AUC på 17%, baseret på data fra 21 patienter.
English: Cases of ileus have been uncommonly reported (see section 4.8).
Danish: Der er indberettet tilfælde af ileus (med frekvensen ”ikke almindelig”se pkt.
English: Time to progression Events n (%) Median a (95% CI)
Danish: Tid indtil progression Hændelser n (%) Median a
English: Vision abnormal*
Danish: blindhed)*
English: • different reconstitution requirements for intravenous (IV) or subcutaneous (SC) use
Danish: • Information om, at kravene til rekonstitution er forskellige ved intravenøs (i.v.)
English: ASEPTIC TECHNIQUE MUST BE STRICTLY OBSERVED THROUGHOUT HANDLING OF BORTEZOMIB HOSPIRA SINCE NO PRESERVATIVE IS PRESENT.
Danish: Det er yderst vigtigt, at der anvendes aseptisk teknik under håndteringen af Bortezomib Hospira, da det ikke indeholder konserveringsmiddel.
English: #, Neurotoxicity, Seizure disorders*, Post herpetic neuralgia, Speech disorder*, Restless legs syndrome, Migraine, Sciatica, Disturbance in attention, Reflexes abnormal*, Parosmia
Danish: #, neurotoksicitet, krampeanfald*, postherpetisk neuralgi, taleforstyrrelser*, restless legs-syndrom, migræne, iskias, opmærksomhedsforstyrrelser, unormale reflekser*, parosmi Sjælden Hjerneblødning*, intrakraniel blødning (inkl.
English: • In cycles 1 to 4, bortezomib is administered twice weekly on days 1, 4, 8, 11, 22, 25, 29 and 32.
Danish: • I cyklus 1 til 4 gives bortezomib to gange om ugen på dag 1, 4, 8, 11, 22, 25, 29 og 32.
English: #, Eye inflammation*, Diplopia, Dry eye*, Eye irritation*, Eye pain, Lacrimation increased, Eye discharge
Danish: #, blefaritis øjeninflammation*, diplopi, tørre øjne*, øjenirritation*, øjensmerter, øget tåreflåd, øjenflåd
English: *RR (Post-induction) CR+nCR
Danish: *RR (efter induktion) CR+nCR
English: Then, Bortezomib Hospira may be reinitiated with one dose level reduction (from 1.3 mg/m2 to 1 mg/m2, or from 1 mg/m2 to
Danish: Derefter kan Bortezomib Hospira reinitieres med en reduktion på 1 dosisniveau (fra 1,3 mg/m2 til 1 mg/m2 eller fra 1 mg/m2 til 0,7
English: Sepsis (inc septic shock)*, Herpes zoster (inc disseminated & ophthalmic), Herpes virus infection*, Bacterial infections*, Upper/lower respiratory tract infection*, Fungal infection*, Herpes simplex*
Danish: dissemineret og oftalmisk), herpes-virusinfektion*, bakterieinfektion*, øvre/nedre luftvejsinfektion*, svampeinfektion*, herpes simplex*
English: If you are given Bortezomib for the treatment of multiple myeloma the side effects you may get are listed below:
Danish: De bivirkninger, du kan opleve, hvis du får bortezomib til behandling af myelomatose, er angivet nedenfor:
English: Bortezomib Hospira treatment must be initiated under supervision of a physician experienced in the treatment of cancer patients, however Bortezomib Hospira may be administered by a healthcare professional experienced in use of chemotherapeutic agents.
Danish: Behandlingen med Bortezomib Hospira skal initieres under tilsyn af en læge med erfaring inden for behandling af cancerpatienter.
English: A drug-drug interaction study assessing the effect of rifampicin, a potent CYP3A4 inducer, on the pharmacokinetics of bortezomib (injected intravenously), showed a mean bortezomib AUC reduction of 45% based on data from 6 patients.
Danish: I et lægemiddelinteraktionsforsøg med undersøgelse af virkningen af rifampicin, en potent CYP3A4induktor, på bortezomibs farmakokinetik (som intravenøs injektion) ses en gennemsnitlig reduktion af bortezomibs AUC på 45%, baseret på data fra 6 patienter.
English: There were 140 patients with ALL or LL enrolled and evaluated for safety; median age was 10 years (range 1 to 26).
Danish: 140 patienter med ALL eller LL blev inkluderet og evalueret for så vidt angår sikkerhed.
English: The reconstituted solution must be inspected visually for particulate matter and discolouration prior to administration.
Danish: Den rekonstituerede opløsning skal før administration undersøges visuelt for partikler og misfarvning.
English: Bortezomib Hospira in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.
Danish: Bortezomib Hospira kombineret med rituximab, cyclophosphamid, doxorubicin og prednison er indiceret til behandling af voksne patienter med tidligere ubehandlet mantle-celle-lymfom, som ikke er egnede til hæmatopoietisk stamcelletransplantation.
English: Very Common Pyrexia*, Fatigue, Asthenia Common
Danish: Meget almindelig Pyreksi*, træthed, asteni Almindelig
English: When bortezomib is given together with dexamethasone, you will receive bortezomib intravenously or subcutaneously as a 21-day treatment cycle and dexamethasone 20 mg is given orally on days 1, 2, 4, 5, 8, 9, 11, and 12, of the bortezomib, 21-day treatment cycle.
Danish: Hvis bortezomib gives sammen med dexamethason, får du bortezomib intravenøst eller subkutant som en 21-dages behandlingscyklus, og dexamethason 20 mg gives gennem munden på dag 1, 2, 4, 5, 8, 9, 11 og 12 i den 21-dages behandlingscyklus med bortezomib.
English: SC use
Danish: og s.c. anvendelse
English: Retreatment of patients with relapsed multiple myeloma In a study in which bortezomib retreatment was administered in 130 patients with relapsed multiple myeloma, who previously had at least partial response on a bortezomib-containing regimen, the most common all-grade adverse events occurring in at least 25% of patients were thrombocytopenia (55%),
Danish: Genbehandling af patienter med recidiverende myelomatose I et forsøg, hvor bortezomib-behandling blev gentaget hos 130 patienter med recidiverende myelomatose, som tidligere havde opnået mindst partielt respons med et regimen, der omfattede bortezomib, var de hyppigste bivirkninger af alle grader, der opstod hos mindst 25% af patienterne, thrombocytopeni (55%), neuropati (40%), anæmi (37%), diarré (35%) og obstipation (28%).
English: • Problems with blood clotting
Danish: • Problemer med blodets størkningsevne
English: RR (Post-transplant) CR+nCR
Danish: RR (efter transplantation) CR+nCR
English: Dysacusis (inc tinnitus)* Uncommon Vertigo*, Hearing impaired (up to and inc deafness)
Danish: tinnitus)* Ikke almindelig Vertigo*, nedsat hørelse (inkl.
English: For additional information concerning melphalan and prednisone, see the corresponding Summary of Product Characteristics.
Danish: Se det relevante produktresumé for yderligere oplysninger om melphalan om prednison.
English: • Severe allergic reaction (anaphylactic reaction) signs of which may include difficulty breathing, chest pain or chest tightness, and/or feeling dizzy/faint, severe itching of the skin or raised lumps on the skin, swelling of the face, lips, tongue and /or throat, which may cause difficulty in swallowing,
Danish: Tegnene på en sådan reaktion kan være vejrtrækningsbesvær, smerter i brystet eller trykken for brystet og/eller svimmelhed/følelse af at skulle besvime, voldsom kløe i huden eller hævede knuder på huden, hævelser i ansigt, læber, tunge og/eller svælg, som kan give synkebesvær, kollaps
English: In a drug-drug interaction study assessing the effect of omeprazole, a potent CYP2C19 inhibitor, on the pharmacokinetics of bortezomib (injected intravenously), there was no significant effect on the pharmacokinetics of bortezomib based on data from 17 patients.
Danish: I et lægemiddelinteraktionsforsøg med undersøgelse af virkningen af omeprazol, en potent CYP2C19hæmmer, på bortezomibs farmakokinetik (som intravenøs injektion) er der ingen signifikant virkning på bortezomibs farmakokinetik, baseret på data fra 17 patienter.
English: Dexamethasone is administered orally at 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12 of the Bortezomib Hospira treatment cycle.
Danish: Dexamethason administreres oralt i en dosis på 20 mg på dag 1, 2, 4, 5, 8, 9, 11 og 12 i behandlingscyklussen med Bortezomib Hospira.
English: When bortezomib is given together with dexamethasone, you will receive bortezomib intravenously or subcutaneously as a 21-day treatment cycle and dexamethasone 40 mg is given orally on days 1, 2, 3, 4, 8, 9, 10 and 11 of the Bortezomib 21-day treatment cycle.
Danish: Hvis bortezomib gives sammen med dexamethason, får du bortezomib intravenøst eller subkutant som en 21-dages behandlingscyklus, og dexamethason 40 mg gives gennem munden på dag 1, 2, 3, 4, 8, 9, 10 og 11 i den 21-dages behandlingscyklus med bortezomib.
English: Log rank test adjusted for stratification factors: ISS staging and number of prior lines.
Danish: Log-rank-test justeret for stratifikationsfaktorer: ISS-stadieinddeling og antal tidligere linjer Medianvarigheden af opfølgning er 11,8 måneder
English: Patients with moderate or severe hepatic impairment should be started on Bortezomib Hospira at a reduced dose of 0.7 mg/m2 per injection during the first treatment cycle, and a subsequent dose escalation to 1.0 mg/m 2 or further dose reduction to 0.5 mg/m 2 may be considered based on patient tolerability (see Table 6 and sections 4.4 and 5.2).
Danish: Patienter med moderat eller alvorligt nedsat leverfunktion skal starte med en reduceret dosis af Bortezomib Hospira på 0,7 mg/m2 pr. injektion i den første behandlingscyklus; efterfølgende dosisøgning til 1,0 mg/m 2 eller yderligere dosisreduktion til 0,5
English: Progression-free survival Events n (%)
Danish: Progressionsfri overlevelse Hændelser n (%) Median a
English: Dexamethasone is administered orally at 40 mg on days 1, 2, 3, 4, 8, 9, 10 and 11 of the Bortezomib Hospira treatment cycle.
Danish: Dexamethason administreres oralt i en dosis på 40 mg på dag 1, 2, 3, 4, 8, 9, 10 og 11 i behandlingscyklussen med Bortezomib Hospira.
English: In dogs, the decreased cardiac contractility and hypotension responded to acute intervention with positive inotropic or pressor agents.
Danish: Akut intervention med positive inotrope midler eller pressorer påvirker den nedsatte hjertekontraktilitet og hypotension hos hunde.
English: Hypokalaemia*, Blood glucose abnormal*, Hyponatraemia*, Diabetes mellitus*, Fluid retention Uncommon Tumour lysis syndrome
Danish: Hypokaliæmi*, unormal blodglucose*, hyponatriæmi*, diabetes mellitus*, væskeretention Ikke almindelig Tumorlysesyndrom
English: All Grade PN
Danish: Seponering på grund af PN
English: 1.2 Before administration, visually inspect the solution for particulate matter and discolouration.
Danish: 1.2 Kontrollér opløsningen for partikler og misfarvning før administration.
English: Similar proportions of patients had creatinine clearance ≤ 30 ml/min (3% in each arm).
Danish: Tilsvarende andele af patienterne havde kreatininclearance ≤ 30
English: CR+nCR+PR 121 (38)b 56 (18)
Danish: CR+nCR+PR 121
English: 1, 4, 8, and 11, followed by a 17-day rest period from day 12 to day 28), dexamethasone (40 mg administered orally on days 1 to 4 and days 8 to 11), and thalidomide (administered orally at 50 mg daily on days 1-14, increased to 100 mg on days 15-28 and thereafter to 200 mg daily).
Danish: Patienterne i BTDx-gruppen fik 6 cyklusser af 4-ugers varihed hver med bortezomib (1,3 mg/m administreret 2 gange om ugen på dag 1, 4, 8 og 11 efterfulgt af en 17-dages pause fra dag 12-28), dexamethason (40 mg administreret oralt på dag 1-4 og dag 8-11) samt thalidomid (administreret oralt med 50 mg dagligt på dag 1-14 og forhøjet til 100 mg på dag 15-28 og derefter til 200 mg dagligt).
English: Intravenous reconstitution: After reconstitution, 1 ml of solution for intravenous injection contains 1 mg bortezomib.
Danish: Rekonstitution før intravenøs anvendelse: Efter rekonstitution indeholder 1 ml injektionsvæske til intravenøs injektion 1 mg bortezomib.
English: After reconstitution, 1 ml of solution for subcutaneous injection contains 2.5 mg bortezomib.
Danish: Efter rekonstitution indeholder 1 ml injektionsvæske til subkutan injektion 2,5 mg bortezomib.
English: Bortezomib Hospira in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.
Danish: Bortezomib Hospira kombineret med melphalan og prednison er indiceret til behandling af voksne patienter med tidligere ubehandlet myelomatose, som er uegnede til højdosis kemoterapi med hæmatopoietisk stamcelletransplantation.
English: • Different types of rash
Danish: • Forskellige former for udslæt
English: Bortezomib Hospira is for intravenous or subcutaneous use.
Danish: Bortezomib Hospira er beregnet til intravenøs eller subkutan anvendelse.
English: • Inflammation or haemorrhage of the blood vessels that can appear as small red or purple dots (usually on the legs) to large bruise-like patches under the skin or tissue
Danish: • Betændelse eller blødning i blodkarrene, der kan vise sig som små rødlige eller lilla prikker
English: Following intravenous bolus administration of a 1.0 mg/m2 and 1.3 mg/m2 dose to 11 patients with multiple myeloma and creatinine clearance values greater than 50 ml/min, the mean first-dose maximum plasma concentrations of bortezomib were 57 and 112 ng/ml, respectively.
Danish: Absorption Efter intravenøs bolusadministration af en dosis på 1,0 mg/m2 og 1,3 mg/m2 til 11 patienter med myelomatose og kreatininclearance-værdier på mere end 50 ml/min.
English: Bortezomib is used for the treatment of multiple myeloma (a cancer of the bone marrow) in patients older than 18 years: - alone or together with the medicines pegylated liposomal doxorubicin or dexamethasone, for patients whose disease is worsening (progressive) after receiving at least one prior treatment and for whom blood stem cell transplantation was not successful or is unsuitable.
Danish: Bortezomib bruges til behandling af myelomatose (kræft i knoglemarven) hos patienter over 18 år: - alene eller sammen med lægemidlerne pegyleret liposomal doxorubicin eller dexamethason til patienter, hvis sygdom forværres (er progressiv) efter mindst én forudgående behandling, og som ikke har haft gavn af eller mulighed for at få en transplantation af blodstamceller - sammen med lægemidlerne melphalan og prednison til behandling af patienter, der ikke tidligere er blevet behandlet for sygdommen, og som ikke er egnede til højdosis-kemoterapi med transplantation af blodstamceller.
English: Uncommon Cardiovascular disorder (inc cardiogenic shock)
Danish: Ikke almindelig Kardiovaskulær sygdom (inkl.
English: • Chest pains or shortness of breath with exercise
Danish: • Brystsmerter eller stakåndethed ved fysisk udfoldelse
English: Cardiac disorders
Danish: kardiogent shock)
English: Bortezomib Hospira 1 mg powder for solution for injection Bortezomib Hospira 2.5 mg powder for solution for injection Bortezomib Hospira 3 mg powder for solution for injection Bortezomib Hospira 3.5 mg powder for solution for injection bortezomib
Danish: Bortezomib Hospira 1 mg pulver til injektionsvæske, opløsning Bortezomib Hospira 2,5 mg pulver til injektionsvæske, opløsning Bortezomib Hospira 3 mg pulver til injektionsvæske, opløsning Bortezomib Hospira 3,5 mg pulver til injektionsvæske, opløsning bortezomib
English: Bortezomib Hospira IS FOR SUBCUTANEOUS OR INTRAVENOUS USE.
Danish: Bortezomib Hospira ER BEREGNET TIL SUBKUTAN ELLER INTRAVENØS ANVENDELSE.
English: Corneal lesion*, Exophthalmos, Retinitis, Scotoma, Eye disorder (inc. eyelid) NOS, Dacryoadenitis acquired, Photophobia, Photopsia, Optic neuropathy
Danish: øjenlåg), akkvisit dacryoadenitis, fotofobi, fotopsi, optisk neuropati
English: > 1.5 x -3 x ULN Any Reduce Bortezomib Hospira to 0.7 mg/m 2 in the first treatment cycle.
Danish: Reducér Bortezomib Hospira til 0,7 mg/m 2 i den første behandlingscyklus.
English: Bortezomib Hospira 1 mg powder for solution for injection Bortezomib Hospira 2.5 mg powder for solution for injection Bortezomib Hospira 3 mg powder for solution for injection Bortezomib Hospira 3.5 mg powder for solution for injection
Danish: Bortezomib Hospira 1 mg pulver til injektionsvæske, opløsning Bortezomib Hospira 2,5 mg pulver til injektionsvæske, opløsning Bortezomib Hospira 3 mg pulver til injektionsvæske, opløsning Bortezomib Hospira 3,5 mg pulver til injektionsvæske, opløsning
English: Peripheral neuropathy in combination regimens
Danish: Perifer neuropati ved kombinationsbehandlinger Myelomatose
English: Dose adjustments during treatment and re-initiation of treatment for combination therapy with melphalan and prednisone Prior to initiating a new cycle of therapy:
Danish: Dosisjusteringer i behandlingsforløbet og ved reinitiering af kombinationsbehandling med melphalan og prednison
English: (e.g., bleeding from your bowels, stomach, mouth and gum or bleeding in the brain or bleeding from the liver) - red blood cells, which can cause anaemia, with symptoms such as tiredness and paleness - white blood cells may make you more prone to infections or flu-like symptoms.
Danish: Du kan opleve et fald i antallet af: - blodplader, hvilket kan gøre dig mere tilbøjelig til at få blå mærker eller til at bløde uden påviselig skade (f.eks. blødning fra tarmene, maven, munden og tandkødet, blødning i hjernen eller blødning fra leveren) - røde blodlegemer, hvilket kan forårsage blodmangel med symptomer som træthed og bleghed
English: • In cycles 5 to 9, bortezomib is administered once weekly on days 1, 8, 22 and 29.
Danish: • I cyklus 5 til 9 gives bortezomib én gang om ugen på dag 1, 8, 22 og 29.